106 related articles for article (PubMed ID: 27992315)
1. Inhibition of the p53 Y220C Mutant by 1-Hydroxy-2- Methylanthraquinone Derivatives: A Novel Strategy for Cancer Therapy.
Ahire V; Das D; Mishra KP; Kulkarni GR; Ackland L
J Environ Pathol Toxicol Oncol; 2016; 35(4):355-364. PubMed ID: 27992315
[TBL] [Abstract][Full Text] [Related]
2. Wild type p53 function in p53
Sundar D; Yu Y; Katiyar SP; Putri JF; Dhanjal JK; Wang J; Sari AN; Kolettas E; Kaul SC; Wadhwa R
J Exp Clin Cancer Res; 2019 Feb; 38(1):103. PubMed ID: 30808373
[TBL] [Abstract][Full Text] [Related]
3. Multifunctional Compounds for Activation of the p53-Y220C Mutant in Cancer.
Miller JJ; Orvain C; Jozi S; Clarke RM; Smith JR; Blanchet A; Gaiddon C; Warren JJ; Storr T
Chemistry; 2018 Dec; 24(67):17734-17742. PubMed ID: 30230059
[TBL] [Abstract][Full Text] [Related]
4. Prediction of dual agents as an activator of mutant p53 and inhibitor of Hsp90 by docking, molecular dynamic simulation and virtual screening.
Abbasi M; Sadeghi-Aliabadi H; Hassanzadeh F; Amanlou M
J Mol Graph Model; 2015 Sep; 61():186-95. PubMed ID: 26277488
[TBL] [Abstract][Full Text] [Related]
5. Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant.
Basse N; Kaar JL; Settanni G; Joerger AC; Rutherford TJ; Fersht AR
Chem Biol; 2010 Jan; 17(1):46-56. PubMed ID: 20142040
[TBL] [Abstract][Full Text] [Related]
6. Virtual screening of p53 mutants reveals Y220S as an additional rescue drug target for PhiKan083 with higher binding characteristics.
Raghavan V; Agrahari M; Gowda DK
Comput Biol Chem; 2019 Jun; 80():398-408. PubMed ID: 31128451
[TBL] [Abstract][Full Text] [Related]
7. Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines.
Baud MGJ; Bauer MR; Verduci L; Dingler FA; Patel KJ; Horil Roy D; Joerger AC; Fersht AR
Eur J Med Chem; 2018 May; 152():101-114. PubMed ID: 29702446
[TBL] [Abstract][Full Text] [Related]
8. Targeting Y220C mutated p53 by Foeniculum vulgare-derived phytochemicals as cancer therapeutics.
Garg S; Singh J; Verma SR
J Mol Model; 2023 Jan; 29(2):55. PubMed ID: 36700982
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53 reactivation by small molecules makes its way to the clinic.
Bykov VJ; Wiman KG
FEBS Lett; 2014 Aug; 588(16):2622-7. PubMed ID: 24768524
[TBL] [Abstract][Full Text] [Related]
10. An in silico algorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein.
Bromley D; Bauer MR; Fersht AR; Daggett V
Protein Eng Des Sel; 2016 Sep; 29(9):377-90. PubMed ID: 27503952
[TBL] [Abstract][Full Text] [Related]
11. Discovery of anti-colon cancer agents targeting wild-type and mutant p53 using computer-aided drug design.
Hadni H; Elhallaoui M
J Biomol Struct Dyn; 2023 Nov; 41(19):10171-10189. PubMed ID: 36533393
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach.
Leão M; Pereira C; Bisio A; Ciribilli Y; Paiva AM; Machado N; Palmeira A; Fernandes MX; Sousa E; Pinto M; Inga A; Saraiva L
Biochem Pharmacol; 2013 May; 85(9):1234-45. PubMed ID: 23428467
[TBL] [Abstract][Full Text] [Related]
13. Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm.
Bauer MR; Krämer A; Settanni G; Jones RN; Ni X; Khan Tareque R; Fersht AR; Spencer J; Joerger AC
ACS Chem Biol; 2020 Mar; 15(3):657-668. PubMed ID: 31990523
[TBL] [Abstract][Full Text] [Related]
14. A molecular dynamics and docking study to screen anti-cancer compounds targeting mutated p53.
Shah HD; Saranath D; Murthy V
J Biomol Struct Dyn; 2022 Apr; 40(6):2407-2416. PubMed ID: 33111621
[TBL] [Abstract][Full Text] [Related]
15. Distinct novel quinazolinone exhibits selective inhibition in MGC-803 cancer cells by dictating mutant p53 function.
Zhang GH; Xue WB; An YF; Yuan JM; Qin JK; Pan CX; Su GF
Eur J Med Chem; 2015 May; 95():377-87. PubMed ID: 25828929
[TBL] [Abstract][Full Text] [Related]
16. Effect of Y220C mutation on p53 and its rescue mechanism: a computer chemistry approach.
Rauf SM; Endou A; Takaba H; Miyamoto A
Protein J; 2013 Jan; 32(1):68-74. PubMed ID: 23315175
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of p53 inactivation by cavity-creating cancer mutations and its implications for the development of mutant p53 reactivators.
Balourdas DI; Markl AM; Krämer A; Settanni G; Joerger AC
Cell Death Dis; 2024 Jun; 15(6):408. PubMed ID: 38862470
[TBL] [Abstract][Full Text] [Related]
18. Different roles of p53 in the regulation of DNA damage caused by 1,2-heteroannelated anthraquinones and doxorubicin.
Chang YL; Lee HJ; Liu ST; Lin YS; Chen TC; Hsieh TY; Huang HS; Huang SM
Int J Biochem Cell Biol; 2011 Dec; 43(12):1720-8. PubMed ID: 21856437
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties.
Punganuru SR; Madala HR; Venugopal SN; Samala R; Mikelis C; Srivenugopal KS
Eur J Med Chem; 2016 Jan; 107():233-44. PubMed ID: 26599530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]